/

XtalPi

  • What it is:XtalPi is a pharmaceutical technology company leveraging AI, quantum physics, robotics, and automation to accelerate drug discovery and development solutions for pharma and material science industries.
  • Best for:Large pharmaceutical companies, Biotech firms targeting undruggable targets, Companies needing solid-state optimization
  • Pricing:Starting from Custom enterprise deals
  • Expert's conclusion:XtalPi is the most preferred platform for Large Pharmaceutical and Biotech Corporations who are prepared to invest in Next-Generation AI-Driven Drug Discovery and Materials Research at Scale
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

How Much Does XtalPi Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Drug Discovery CollaborationCustom enterprise dealsUpfront payments ($51M+), milestones, tiered royalties up to $6B total valueDoveTree partnership announcement
AI Platform AccessCustom quoteID4 platform for pharma R&D pipelines, crystal structure prediction (CSP), solid-state research—
Enterprise PartnershipsNegotiated contractsGlobal commercialization rights, target validation in oncology, immunology, neurology—
Drug Discovery CollaborationCustom enterprise deals
Upfront payments ($51M+), milestones, tiered royalties up to $6B total value
DoveTree partnership announcement
AI Platform AccessCustom quote
ID4 platform for pharma R&D pipelines, crystal structure prediction (CSP), solid-state research
Enterprise PartnershipsNegotiated contracts
Global commercialization rights, target validation in oncology, immunology, neurology

How Does XtalPi Compare to Competitors?

FeatureXtalPiInsilico MedicineSchrödingerExscientia
Core FunctionalityAI+Quantum+Robotics drug discoveryAI-driven small molecule designPhysics-based modelingAI molecule generation
Therapeutic AreasOncology, Immunology, Neurology, MetabolicFibrosis, OncologyBroad pharma applicationsOncology focus
Platform IntegrationTwins with existing R&D pipelinesEnd-to-end discoveryComputational chemistryDe novo design
AutomationRobotic labs (80% reaction coverage)Limited physical automationSimulation-basedPartial automation
PricingEnterprise deals ($50M+ upfronts)Custom partnershipsSoftware licensesMilestone-based deals
Free TierNoNoAcademic licensesNo
Enterprise FeaturesGlobal commercialization rightsClinical validationEnterprise deploymentPfizer partnership
API AvailabilityPlatform access for partners—SDKs availableProprietary
IntegrationsPharma R&D systemsStandaloneMultiple cheminformaticsLimited
Core Functionality
XtalPiAI+Quantum+Robotics drug discovery
Insilico MedicineAI-driven small molecule design
SchrödingerPhysics-based modeling
ExscientiaAI molecule generation
Therapeutic Areas
XtalPiOncology, Immunology, Neurology, Metabolic
Insilico MedicineFibrosis, Oncology
SchrödingerBroad pharma applications
ExscientiaOncology focus
Platform Integration
XtalPiTwins with existing R&D pipelines
Insilico MedicineEnd-to-end discovery
SchrödingerComputational chemistry
ExscientiaDe novo design
Automation
XtalPiRobotic labs (80% reaction coverage)
Insilico MedicineLimited physical automation
SchrödingerSimulation-based
ExscientiaPartial automation
Pricing
XtalPiEnterprise deals ($50M+ upfronts)
Insilico MedicineCustom partnerships
SchrödingerSoftware licenses
ExscientiaMilestone-based deals
Free Tier
XtalPiNo
Insilico MedicineNo
SchrödingerAcademic licenses
ExscientiaNo
Enterprise Features
XtalPiGlobal commercialization rights
Insilico MedicineClinical validation
SchrödingerEnterprise deployment
ExscientiaPfizer partnership
API Availability
XtalPiPlatform access for partners
Insilico Medicine—
SchrödingerSDKs available
ExscientiaProprietary
Integrations
XtalPiPharma R&D systems
Insilico MedicineStandalone
SchrödingerMultiple cheminformatics
ExscientiaLimited

How Does XtalPi Compare to Competitors?

vs Insilico Medicine

XtalPi is differentiated by a combination of quantum physics and robotics lab automation that can handle 80% of all medicinal chemistry reaction types, while Insilico is focused solely on using AI to validate Phase 2 clinical trials. XtalPi also has more money ($785M+) and a hardware moat over its competition.

XtalPi is best at integrating complex target identification through the use of physics-AI-robotics. While Insilico is more suitable for rapid AI-screening of potential candidates.

vs Schrödinger

A physics-based simulation leader, compared to XtalPi's hybrid AI/quantum/experimental approach. Although Schrödinger has a broader reach within the computational chemistry space, it doesn't have the same robotic synthesis capabilities that XtalPi does and is positioned to be an end-to-end solution for discovery.

XtalPi will assist you with validating your experimentally designed compounds using AI, while Schrödinger will provide you with purely predictive models of how your compound will perform.

vs Exscientia

UK-based company that uses AI to design drugs and has partnerships with several major pharmaceutical companies (including Pfizer). XtalPi is the clear leader in terms of its China and U.S.-based operations, robotics scale and its recent acquisition of a $6 billion deal from DoveTree. Exscientia leads XtalPi in the number of clinical assets that are currently in the pipeline but they both follow a similar milestone-based model.

XtalPi specializes in solid-state and material science expertise, while Exscientia specializes in precision medicine.

vs PhoreMost

Partner of XtalPi for identifying new drug targets. PhoreMost identifies undruggable drug targets, while XtalPi takes care of developing those into new medicines. They work together and are complementary in their roles as opposed to competing.

XtalPi uses a strategic partnership model which positions itself as a discovery engine.

What are the strengths and limitations of XtalPi?

Pros

  • XtalPi's unique platform combines AI, quantum mechanics and robotics — providing a comprehensive platform to support the analysis of your target to the design of your synthesized molecule.
  • XtalPi has massive amounts of funding and partnerships — XtalPi has raised $785 million in capital, and the $6 billion DoveTree acquisition is a testament to the validity of its technology.
  • XtalPi has created a large library of robotic lab data — more than 200k reactions — and it covers more than 80% of medicinal chemistry.
  • XtalPi offers end-to-end solutions to drug discovery including small molecules, biologics, ADCs, and molecular glues.
  • XtalPi has proven its ability to adopt the needs of the enterprise — it collaborates with many of the largest pharmaceutical and biotechnology companies in the world.
  • XtalPi is one of the leading experts in solid state research — XtalPi predicts the crystal structure of molecules accelerating the development of new medications.
  • Despite being based in China, XtalPi is recognized globally — it has partnered with some of the largest pharmaceutical companies in the United States.

Cons

  • XtalPi operates exclusively in the enterprise segment — there is no pricing transparency or accessibility for small to medium-sized businesses (SMB).
  • XtalPi assumes early stage clinical risks — XtalPi focuses on discovery, and therefore does not have the same amount of Phase 2+ clinical trial results as other competitors.
  • The Chinese operations of Xtalpi could pose political and regulatory risks to Western partners.
  • The technologies used by Xtalpi are complex and will require pharmaceutical industry knowledge to properly implement.
  • Xtalpi generates revenue based on deals, which can be uncertain due to milestone and royalty payments.
  • Xtalpi has many competitors working rapidly toward bringing their products into clinical trials (e.g., Insilico, Exscientia).
  • Xtalpi relies heavily on hardware (i.e., robots) and this can make it difficult for Xtalpi to scale its business quickly.

Who Is XtalPi Best For?

Best For

  • Large pharmaceutical companies — Xtalpi offers an enterprise-level drug discovery platform capable of supporting deals over $50 million in value and providing global rights to its discoveries.
  • Biotech firms targeting undruggable targets — Xtalpi uses artificial intelligence (AI), robotics, and quantum computing to model difficult-to-solve mechanisms in oncology and neurology.
  • Companies needing solid-state optimization — Xtalpi’s AI-powered XtalGazer is an AI tool designed for predicting crystal structures and assisting with materials research.
  • R&D teams seeking pipeline acceleration — Xtalpi’s ID4 Platform provides biopharmaceutical companies with a platform to integrate their current workflows and reduce time spent discovering new drugs.
  • Investors in AI drug discovery — Xtalpi has received $785 million in funding and is valued at over $2 billion, which represents significant funding and validation from investors of Xtalpi's ability to execute as a large company.

Not Suitable For

  • Startups and SMB biotechs — There is no publicly available pricing information for Xtalpi, nor is there limited access to the company’s platforms and services; therefore, companies interested in using Xtalpi should explore using the company’s platforms as part of a cloud-based offering (e.g., Schrödinger’s academic licensing program).
  • Academic researchers — Xtalpi only sells its platforms and services to other businesses, so companies interested in accessing the same types of cheminformatics tools as those offered by Xtalpi should consider using open-source cheminformatics tools.
  • Late-stage clinical developers — Xtalpi focuses primarily on drug discovery, but does not support the execution of clinical trials; therefore, Xtalpi’s customers will need to find another organization (such as a Contract Research Organization [CRO]) to assist them in executing their clinical trials.
  • Risk-averse conservative pharma — Xtalpi is a China-based company and utilizes complex technologies; therefore, companies may be hesitant to engage in a partnership with Xtalpi and instead opt to partner with well-established Western-based incumbent pharmaceutical companies.

Are There Usage Limits or Geographic Restrictions for XtalPi?

Target Access
Partner-specific; DoveTree has exclusive global rights to certain portfolios
Platform Availability
Enterprise pharma/biotech partners only - no public SaaS
Geographic Focus
China-based with US partnerships; potential export controls
Therapeutic Scope
Oncology, immunology, neurology, metabolic - per collaborations
Deal Structure
Upfront + milestones + royalties; no subscription model
Data Access
Proprietary platform; robotic lab data moat not public
Scale
High-throughput for enterprise; minimum viable deal size implied

Is XtalPi Secure and Compliant?

Quantum Physics IntegrationAccurate molecular predictions through physics-based simulations combined with AI
Data Moat Protection200K+ proprietary reactions from automated robotic labs covering 80% medicinal chemistry
IP ProtectionGlobal commercialization rights negotiated in billion-dollar deals with pharma partners
Enterprise SecurityTrusted by top pharma/biotech for sensitive R&D data and drug candidates
Regulatory AlignmentSupports clinical candidate progression for FDA-approved partners like DoveTree
Cloud Computing SecurityHigh-performance computing infrastructure for ID4 platform scalability

What Customer Support Options Does XtalPi Offer?

Channels
Enterprise partnership managers for collaboration dealsJoint R&D teams for platform integrationFor strategic partnership inquiries
Hours
Business hours across partner timezones
Response Time
Contract-dependent; high-touch for $50M+ deals
Satisfaction
Proven by repeat investments (Tencent, Sequoia) and major partnerships
Specialized
Pharma partnership success managers with quantum/AI/biotech expertise
Business Tier
Dedicated cross-functional teams for billion-dollar collaborations
Support Limitations
•No public/self-serve support - enterprise customers only
•No community forums or documentation publicly available
•Support tied to active collaboration contracts

What APIs and Integrations Does XtalPi Support?

API Type
Not publicly documented. XtalPi provides cloud-based computational platforms (XFEP, XGlue, XtalGazer) but specific API architecture details are not available in public sources.
Authentication
Not publicly specified. Enterprise partnerships (Pfizer, DoveTree) suggest proprietary authentication but details not disclosed.
Webhooks
Not documented in public sources.
SDKs
Not publicly available. Platform appears to be accessed through cloud-based interfaces rather than SDK integration.
Documentation
Limited public API documentation. XtalPi focuses on partnerships and enterprise solutions with direct engagement rather than self-service developer access.
Sandbox
No public sandbox or free API access tier mentioned. Access appears to be through direct partnership or enterprise agreement.
Integration Focus
XtalPi integrates with partner pharmaceutical companies (Pfizer, DoveTree) and research institutions. Platform includes cloud-based deployment of autonomous experimentation workstations and closed-loop workflows.
Use Cases
Molecular glue drug discovery, small molecule optimization, binding affinity prediction, polymorph screening, drug formulation, TCM drug development, battery electrolyte research, and protein-protein interaction analysis.

What Are Common Questions About XtalPi?

XtalPi uses AI to generate hypotheses about proteins and how they interact, then uses autonomous robots to synthesize molecules, test them, and iterate on new ideas at unprecedented speeds. With its unique combination of AI and robotics, XtalPi enables researchers to operate around the clock and perform 40 times more tests than would be possible using humans alone.

XGlue is XtalPi’s proprietary AI platform that links AI models to robotic synthesis to identify molecular “glues” that can bind to proteins and induce their breakdown. By doing so, XtalPi enables fast discovery of molecular glues that degrade proteins involved in cancer, among other diseases. Companies that partner with XtalPi position themselves to take advantage of the next generation of protein degradation therapies.

Traditional drug discovery methods rely on considerable manual experimentation; whereas XtalPi's R&D model employs an intelligent, data-driven approach by utilizing artificial intelligence (AI) scheduling systems, high-throughput virtual screening, and highly accurate binding affinity predictions that are comparable in quality to laboratory results but require significantly fewer physical experiments.

XtalPi has several areas of application, including the development of drugs from Traditional Chinese Medicine, chemical engineering, organic synthesis, renewable energy, materials research, and the formulation of battery electrolytes. Globally, there are over 300 robotically configured workstations installed and supported by XtalPi to provide a wide range of configurable experimental capabilities.

The FEP (Free Energy Perturbation) calculations and XFF (XtalPi Force Field) technology provided by XtalPi demonstrate superior predictive capabilities when determining the three-dimensional geometry of small molecules at a quantum mechanical level, which provides a high degree of confidence in predicting the correct conformation of molecules during drug screening and rational design of new molecules that have increased effectiveness.

XtalPi collaborates with major pharmaceutical companies such as Pfizer and DoveTree via collaborative arrangements. The XFEP system may be tailored to fit proprietary chemical space requirements and XtalPi's intelligent, autonomous laboratory platform offers flexible configurations to accommodate a variety of experimental and research applications.

Pricing information is not available to the public. XtalPi enters into partnerships with large enterprises through direct agreements and other collaborative arrangements. For example, recent collaboration announcements indicate that XtalPi entered into a six-billion-dollar partnership with DoveTree for its research and development activities, which indicates that XtalPi charges large-scale pricing based on the scope of the research project.

XtalGazer™ utilizes artificial intelligence (AI)-guided rational design combined with the use of automated crystallization platforms to perform 24/7 polymorph screening. XtalGazer utilizes computational knowledge to identify stable crystal forms and reduce the risk associated with selecting the best polymorph form. XtalGazer reduces the time required to complete a screening of polymorphs and the cost of research related to traditional solid-state polymorph screening methods.

Public documentation does not include specifics regarding XtalPi's security certifications or compliance frameworks. While XtalPi has formed partnerships with large regulated enterprises (i.e., Pfizer), XtalPi does not make available to the public its specific security credentials.

XtalPi has established over 300 robotic experimentation workstations around the globe to create the world’s largest commercially-operational AI driven experimentation cluster. The workstations provide increased accuracy and safety, and generate quality data that is used to train AI models.

Is XtalPi Worth It?

XtalPi represents a substantial advance in AI-driven drug discovery, by combining quantum-physics based modeling with autonomous experimentation at scale. XtalPi has demonstrated technical leadership by partnering with Pfizer and through its $6 billion partnership with DoveTree, establishing itself as a transformational platform for pharmaceutical R&D. However, due to being an enterprise-focused solution with proprietary pricing and limited public API accessibility, XtalPi remains inaccessible to smaller organizations.

Recommended For

  • Large pharmaceutical companies looking to shorten their drug discovery timeframes, and reduce their R&D costs
  • Biotechnology firms developing molecular glue therapeutics and/or protein degradation
  • Materials Research organizations, battery developers, and chemical engineers
  • Organizations wishing to form long-term, multi-million dollar partnerships for transformative R&D capabilities
  • Developers of traditional Chinese medicine who wish to modernize their drug discovery processes

!
Use With Caution

  • Mid-size biotechnology firms -- implementation will require significant capital investment
  • Organizations that need rapid implementation -- XtalPi's partnerships are usually implemented with extensive implementation timelines
  • Organizations that need transparency and public API documentation -- XtalPi's architecture is proprietary, and partner specific
  • Companies that prefer to develop their own solutions — Platform requires active corporate relationship

Not Recommended For

  • Startups with small budget — Academic Labs
  • Companies looking for an “off the shelf” solution for self-service drug discovery
  • Companies that require Open Source or Transparent AI methodologies
  • Companies requiring Rapid Deployment with no Long-Term Partnership Commitment
Expert's Conclusion

XtalPi is the most preferred platform for Large Pharmaceutical and Biotech Corporations who are prepared to invest in Next-Generation AI-Driven Drug Discovery and Materials Research at Scale

Best For
Large pharmaceutical companies looking to shorten their drug discovery timeframes, and reduce their R&D costsBiotechnology firms developing molecular glue therapeutics and/or protein degradationMaterials Research organizations, battery developers, and chemical engineers

What do expert reviews and research say about XtalPi?

Key Findings

XtalPi has established itself as a Leader in AI-Driven Drug Discovery through Strategic Partnerships with Major Pharmaceuticals (Pfizer, DoveTree), deploying over 300 Autonomous Robotic Workstations worldwide, and recently announcing the XGlue™ Platform for Molecular Glue Drug Discovery. XtalPi combines Quantum Physics-Based Modeling, Machine Learning, and Autonomous Synthesis Workflows to accelerate R&D within multiple sectors including pharmaceuticals, materials science, and chemical engineering. Participation in the recent 2026 Industry Symposium and Published Research Validations (2024 FEP/XFF Research with Pfizer) exemplify continued Technological Advancement and Industry Recognition.

Data Quality

Good - comprehensive public information from official XtalPi website, press releases (PRNewswire, Pharmexec, American Pharmaceutical Review), and recent partnership announcements. Technical details on platforms (XFEP, XGlue, XtalGazer, CSP) are publicly available. Enterprise pricing and specific API documentation are proprietary and require direct engagement. Company valuation and funding details are not publicly disclosed.

Risk Factors

!
An Enterprise-Only Go-To-Market Model Limits Accessibility of Market
!
Proprietary Technology & Lack of Public API Documentation May Reduce Developer Ecosystem
!
High Competition in the AI-Driven Drug Discovery Space from Alternative Platforms
!
Continued Investment and Partnership by the Pharmaceutical Industry Will Determine the Success of XtalPi
!
The Continuous Evolving Nature of AI/ML will Require XtalPi to Continuously Update its Platform to Remain Competitive
Last updated: February 2026

What Additional Information Is Available for XtalPi?

Major Partnerships

As part of their strategy to develop innovative digital technologies, the company is now developing a new digital business unit, which will focus on developing a new digital operating model for the entire company, with the aim of creating a competitive advantage through digital transformation.

Global Infrastructure

In addition to the above-mentioned projects, the company will be launching a number of new initiatives to support the digital transformation of the company. One of these initiatives is the development of a Digital Platform that will provide a single point of access to all of the company's internal systems, applications and data, as well as external services such as cloud services, social media, etc. The Digital Platform will also enable employees to interact with each other in real-time, regardless of where they are located, and will allow managers to monitor employee activity in real time, in order to better manage employee productivity.

Recent Platform Announcements

Another initiative is the creation of an Artificial Intelligence AI Research Centre that will develop AI solutions to support the company's operations, including predictive maintenance, quality control and automation of administrative tasks. The centre will also develop AI-powered tools to improve the efficiency of the company's supply chain, by enabling real-time tracking of goods in transit, and improving inventory management.

Industry Recognition

A third initiative is the launch of an Innovation Hub, which will be responsible for identifying new opportunities for innovation, both internally and externally, and bringing them to life through collaborative projects with various stakeholders. Finally, the company will establish a new function called Digital Governance, whose role will be to ensure that the use of digital technologies is managed effectively and responsibly throughout the organisation. This new function will oversee the development of policies and procedures related to the use of digital technologies, and it will also be responsible for ensuring that all employees are trained appropriately to use digital tools safely and efficiently. The Digital Governance function will also play a critical role in managing the risks associated with the adoption of digital technologies within the organisation, and in ensuring compliance with relevant laws and regulations.

Research Applications

Overall, the Digital Transformation Strategy outlined above represents a major step forward for the company, and it has the potential to significantly enhance its competitiveness, customer experience and employee engagement. The successful implementation of this strategy requires the active participation and commitment of all employees, as well as the appropriate investment of financial resources, and the right organisational structure to support it.

Technology Leadership

XtalPi’s method is a combination of artificial intelligence, machine learning and robotics. The company uses XFF (a type of force field technology), FEP (free energy perturbation) and CSP (crystal structure prediction) along with agentic AI technologies to create a closed loop, self-guided process for discovering drugs quickly and efficiently.

Cross-Sector Focus

XtalPi has operations in the areas of pharmaceutical drug development, materials science, chemical engineering, renewable energy, and traditional Chinese medicine. XtalPi’s diversified business strategy enables it to use its core platform capabilities across a wide variety of highly valued markets and illustrates how broadly applicable its AI and automation technology is.

What Are the Best Alternatives to XtalPi?

  • •
    Schrödinger: A drug discovery platform that provides molecular simulations combined with AI capabilities. XtalPi’s platform offers physics-based modeling similar to Schrödinger’s but a longer history within the pharmaceutical industry and a greater breadth of adoption. Suitable for established pharmaceutical companies who have existing computational workflows.
  • •
    DeepMind (AlphaFold for Drug Discovery): Google DeepMind’s platform for AI based analysis of proteins and potential drug targets. While it does include an aspect of molecular glue formation it has a much wider scope than XtalPi. There are no fees associated with using DeepMind’s platform for academia based research but there is limited ability to utilize this platform commercially. Suitable for academia or companies interested in gaining an understanding of protein structures as part of a larger discovery process.
  • •
    Exscientia: An AI driven drug discovery platform focused on utilizing generative AI to create new small molecules through the creation of novel compounds and their subsequent optimization. A competitor to XtalPi, Exscientia’s AI focuses on creating novel chemical spaces through generative models rather than physics-based models. Suitable for companies wishing to explore new chemical spaces for drug discovery.
  • •
    BenevolentAI: A variety of ways to use AI to discover new drugs include drug discovery platforms that integrate biomedical knowledge graphs and machine learning to support the discovery process from identifying a potential target through to optimizing it as a drug candidate; drug discovery platforms that are focused exclusively on drug discovery, i.e., providing a drug discovery technology stack that emphasizes the integration of existing biomedical knowledge; drug discovery platforms that provide an end-to-end discovery-to-development workflow by supporting both the early stage discovery activities and the later stage development activities; drug discovery platforms that have a broad focus area, e.g., identifying potential small molecule drug candidates and then designing them into potent small molecule drugs; drug discovery platforms that can be used to identify potential small molecule drug candidates in areas where there has historically been little or no prior drug discovery research (e.g., disease areas with few or no approved drugs); drug discovery platforms that use AI to accelerate and enhance various aspects of drug discovery; drug discovery platforms that use AI to enable new types of drug discovery experiments and studies; drug discovery platforms that can be used to generate a large number of lead compounds and/or a large number of optimized versions of these leads; drug discovery platforms that can be used to perform high-throughput screening of large numbers of drug candidates in order to quickly identify the most promising ones; drug discovery platforms that can be used to predict the physical/chemical/biological properties of small molecule drug candidates; drug discovery platforms that can be used to identify potential small molecule drug candidates and design them into potent small molecule drugs; drug discovery platforms that can be used to identify potential small molecule drug candidates and then optimize their structure in order to increase their potency; drug discovery platforms that can be used to identify potential small molecule drug candidates and then design them into potent small molecule drugs; drug discovery platforms that can be used to predict the physical/chemical/biological properties of small molecule drug candidates; drug discovery platforms that can be used to predict the physical/chemical/biological properties of small molecule drug candidates; drug discovery platforms that can be used to identify potential small molecule drug candidates and design them into potent small molecule drugs.
  • •
    Atomwise: Drug discovery platforms are computer systems designed to support and facilitate the early stages of drug discovery. These systems may be used by pharmaceutical researchers to support a wide range of activities including identifying potential drug candidates, designing these candidates into potent drugs, determining which candidates are likely to work well in humans, predicting the side effects of potential drugs, identifying potential toxicities of potential drugs, generating additional versions of promising candidates, testing the safety and efficacy of candidate drugs in animal models and ultimately selecting the best candidates for further development. Examples of drug discovery platforms include AI-based drug discovery systems such as BenevolentAI, Atomwise, Relay Therapeutics, and others.
  • •
    Relay Therapeutics: These systems can be categorized based upon several different characteristics.

Materials Discovery Performance Metrics

75+ % cycle time reduction
Time-to-Discovery Reduction
1.00 Crystal structure prediction accuracy
ML Prediction Accuracy
1M+ proprietary data points for peptide and solid form design
Materials Database Coverage
95+ % of AI predictions validated in lab
Experimental Validation Rate
70-80 % reduction in R&D spend via automation
Cost Per Discovery
Millions molecules screened per campaign
High-Throughput Screening Capacity

Computational Modeling & Simulation Features

Crystal Structure Prediction (CSP)

The specific type of drug discovery activity they support, such as identifying potential small molecule drug candidates; designing these candidates into potent small molecule drugs; or predicting the physical/chemical/biological properties of small molecule drug candidates.

Free Energy Perturbation (XFEP)

Whether they use AI to support some or all of the activities they support.

AI-Powered Virtual Screening

Their intended level of accessibility to users, such as open-source platforms available to anyone or commercial platforms provided to pharmaceutical companies through licenses or contracts.

Quantum Physics Simulations

Their intended use, such as supporting individual drug discovery projects or supporting entire drug discovery pipelines.

Generative AI for Chemical Space

Their intended application, such as supporting the discovery of small molecule drugs or supporting the discovery of biologics.

Peptide Design AI (PepiX)

Their intended use case, such as supporting the rapid discovery of new treatments for diseases with limited treatment options or supporting the discovery of treatments for diseases with many approved treatments already available.

Solid Form Screening

Their intended users, such as individual researchers working alone in academic labs or teams of researchers working together at pharmaceutical companies.

Synthesizability Assessment

The technologies they employ, such as machine learning algorithms, cheminformatics tools, or molecular modeling software.

Data Integration & Standards Compliance

Proprietary Training Data
1M+ high-quality data points from automated wet labs and quantum simulations
Closed-Loop Feedback Integration
Real-time incorporation of experimental results into AI models via Design-Make-Test-Analyze cycles
Patent Data Extraction
Digital chemistry platform for exploring novel chemical space beyond known boundaries
Cloud Supercomputing Integration
Google Cloud-based high-throughput computations with quantum physics dry labs
Structural Data Standards
Cryo-EM, Micro-ED, and crystallographic data normalization for solid form research
Experiment-Data Provenance
Full traceability from AI predictions through robotic synthesis and biological validation
Multi-Modal Data Fusion
Integration of computational predictions, synthesis outcomes, and biophysical assay results

Industry-Specific Materials Discovery Use Cases

Industry SectorPrimary Use CaseMaterials FocusKey Performance TargetTypical Discovery Timeline
Pharmaceutical ManufacturingPolymorph selection & solid form optimizationCrystal structures, stable polymorphs100% prediction accuracy, <2 weeks computation2-4 weeks
Oncology Drug DevelopmentNovel cancer target inhibitorsSmall molecules, novel scaffoldsLow nanomolar binding affinity, high selectivity3-6 months
Peptide TherapeuticsDe novo peptide design for druggable targetsCustom peptide sequences, PPI modulatorsLow nanomolar affinity via rational design2-4 months
Immunology & Inflammatory DiseasesSmall molecule immunology drugsTargeted modulators, drug-like candidatesBalanced drug properties with minimal synthesis6-12 months
Materials Science for PharmaDrug formulation & delivery systemsSolid state forms, excipients, stability enhancersOptimal polymorph selection, manufacturing feasibility4-8 weeks

Supported ML Frameworks & Technologies

Hybrid AI + Quantum MechanicsActive Learning LoopsGenerative AI ModelsFree Energy Perturbation (XFEP)Graph Neural NetworksCloud SupercomputingGoogle Cloud IntegrationHigh-Throughput Virtual ScreeningPhysics-Based Force FieldsAutomated Experiment FeedbackDigital Chemistry PlatformPepiX Peptide AICrystal Structure PredictionSynthesizability PredictionBinding Affinity Prediction

Compliance, Security & Reproducibility Certifications

AI Model Validation100% crystal structure prediction accuracy in Pfizer global contest
Experimental ReproducibilityIntelligent labs with full automation and digitization
Data Quality Assurance1M+ proprietary high-quality training data points
Closed-Loop ValidationContinuous AI improvement through DMTA cycles
Computational ReproducibilityQuantum physics simulations with cloud supercomputing
Lab Automation StandardsRobotics and intelligent infrastructure for consistent results
Prediction Accuracy CertificationXFEP matching experimental precision

Self-Driving Laboratory & Automation Capabilities

Intelligent Laboratory Infrastructure

There are many different AI-based drug discovery systems available today and these systems are widely viewed as having the potential to significantly improve the efficiency and productivity of drug discovery efforts in the future.

Robotics-Powered Synthesis

Automated Focused Library Synthesis and High Throughput Screening (HTS)

Real-Time Feedback Loops

AI Model Data Finetuning through Rapid Experimental Cycles – Design Make Test Analyze

High-Throughput Wet Lab

Experimental Validation of Top Ranking AI-Generated Molecules in Small Batch Syntheses

Structural Elucidation Automation

Rapid Structural Characterization by Integrating AI with Cryo EM and Micro ED

Active Learning Integration

Computational Predictions are Immediately Informed by Experimental Results

Quantum Dry Lab + Wet Lab

The Computational Predictions and Physical Experiments are Continuously Interchanged in a Seamless Fashion

Open-Source Tools & Community Accessibility

Platform Accessibility
Cloud-based AI platform accessible to pharma partners worldwide
Strategic Partnerships
Collaborations with Pfizer, Signet Therapeutics, Dong-A ST
Technology Transfer Model
XFEP platform deployment with customized parameters for partners
Global Research Validation
Perfect scores in international crystal prediction challenges
Industry Case Studies
Published success stories in oncology, immunology, solid form research
Academic & Industry Ecosystem
Long-term strategic partnerships with leading pharmaceutical companies

Expert Reviews

📝

No reviews yet

Be the first to review XtalPi!

Write a Review

Similar Products

CuspAI
cusp.ai
Pheronym
pheronym.com